Effects of Metformin, Metformin Plus Rosiglitazone, and Metformin Plus Lifestyle on Insulin Sensitivity and β-Cell Function in TODAY
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) trial demonstrated that combination therapy with metformin plus rosiglitazone provided superior durability of glycemic control compared with metformin alone, with significantly lower treatment failure rates (38.6 vs. 51.7%), and metformin plus lifestyle was intermediate. Herein we describe the temporal changes in measures of β-cell function and insulin sensitivity over a 4-year period among the three treatments. RESEARCH DESIGN AND METHODS: TODAY participants (699) were tested periodically with an oral glucose tolerance test to determine insulin sensitivity (1/fasting insulin [1/IF]), insulinogenic index (△I30/△G30) or C-peptide index (△C30/△G30), and β-cell function relative to insulin sensitivity (oral disposition index [oDI]). RESULTS: During the first 6 months, metformin plus rosiglitazone exhibited a significantly greater improvement in insulin sensitivity and oDI versus metformin alone and versus metformin plus lifestyle; these improvements were sustained over 48 months of TODAY. Irrespective of treatment, those who failed to maintain glycemic control had significantly lower β-cell function (∼50%), higher fasting glucose concentration, and higher HbA1c at randomization compared with those who did not fail. CONCLUSIONS: The beneficial change in insulin sensitivity and the resultant lower burden on β-cell function achieved in the first 6 months with metformin plus rosiglitazone appear to be responsible for its superior glycemic durability over metformin alone and metformin plus lifestyle. However, initial β-cell reserve and HbA1c at randomization are independent predictors of glycemic durability. Therefore, efforts to preserve β-cell function before significant loss occurs and to reduce HbA1c may be beneficial in the treatment of youth with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Baseline adjusted geometric mean ± SE asymmetric limits (obtained as exp[mean ± SE of log values]) of OGTT-derived measures of insulin sensitivity (1/IF) (A), insulinogenic index (△I30/△G30) (B), and oDI ([1/IF] × [△C30/△G30]) (C) in the three treatment groups over 48 months of follow-up in TODAY, analyzed using log-transformed values. The P value refers to the overall effect of treatment group assignment in the longitudinal models for the various parameters under question within the groups.](https://figures.cochat.ai/paper-figures/be1b067684cd4881bcf619e3acd41518/effects-of-metformin-metformin-plus-rosiglitazone-and-metformin-plus-lifestyle-figure-1.jpg)
![Figure 2 Baseline adjusted geometric mean ± SE asymmetric limits (obtained as exp[mean ± SE of log values]) of OGTT-derived measures by treatment failure with the three treatment groups combined, analyzed using log-transformed values. A: Insulin sensitivity (1/IF). B: Insulinogenic index (△I30/△G30). C: oDI ([1/IF] × [△C30/△G30]). The P value refers to the overall effect of failed vs. not failed group assignment in the longitudinal models for the various parameters under question within the two groups.](https://figures.cochat.ai/paper-figures/20b5098a6cb74952b4dc2dac4d181449/effects-of-metformin-metformin-plus-rosiglitazone-and-metformin-plus-lifestyle-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Affected young people have a more rapid deterioration in blood glucose levels, an attenuated response to diabetes medication, and more rapid development of diabetes complications (269 -273).”
From Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2022) · cites this paper as [272]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A 20-35 % decline in beta cell function annually in 10-19 year olds has been reported compared to the ~7% loss in older individuals with T2DM 23 .”
From Type 2 diabetes in adolescents and young adults (2018) · cites this paper as [23]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Once treated with metformin after progressing to T2D, youth show a greater rate of treatment failure than adults ( 52 ).”
From β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment (2014) · cites this paper as [52]
In the citing paper
“Early-onset T2DM is also associated with a more aggressive disease phenotype than later-onset T2DM, characterized by a faster β-cell decline (4), higher glycated hemoglobin (HbA1C), higher body mass index (BMI), a more adverse cardiometabolic risk factor profile (5), earlier insulin dependence (6) and a greater risk of both microvascular and macrovascular complications (4).”
From Living with early-onset type 2 diabetes in young adulthood: a narrative review of lived experience and implications for developmentally appropriate care (2026) · cites this paper as [4]
In the citing paper
“β-Cell dysfunction is associated with impaired glycemic control and a greater likelihood of treatment failure in both younger and older adults with T2DM [43,46].”
From Management of Early-Onset Type 2 Diabetes in Adults: Current Evidence and Future Directions (2025) · cites this paper as [43]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
A Clinical Trial to Maintain Glycemic Control in Youth with Type 2 Diabetes
TODAY Study Group (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109333 · Cited by 971
Self-citationThe Importance of β-Cell Failure in the Development and Progression of Type 2 Diabetes
Kahn, S. E. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.9.7713 · Cited by 660
Copeland, K. C., Zeitler, P., Geffner, M., Guandalini, C., Higgins, J., Hirst, K., Kaufman, F. R., Linder, B., Marcovina, S., McGuigan, P., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1642 · Cited by 464
Effect of Metformin in Pediatric Patients With Type 2 Diabetes
Jones, K. L., Arslanian, S., Peterokova, V. A., Park, J.-S., & Tomlinson, M. J. (2002) · Diabetes Care · doi:10.2337/diacare.25.1.89 · Cited by 392 · cited 1×
“Even though metformin was effective in the short-term over 16 weeks (2), it remained unknown whether this effect was durable until the results of the TODAY (Treatment Options for type 2 Diabetes in Adolescents andYouth) trial showed.”
BackgroundThe TODAY Study Group (2007) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2007.00237.x · Cited by 260
Self-citationKahn, S. E., Lachin, J. M., Zinman, B., Haffner, S. M., Aftring, R. P., Paul, G., Kravitz, B. G., Herman, W. H., Viberti, G., Holman, R. R., et al. (2011) · Diabetes · doi:10.2337/db10-1392 · Cited by 249 · cited 5×
“The ADOPT (A Diabetes Outcome Progression Trial) study of drugnaive adults with type 2 diabetes showed that the insulinogenic index declined at a rate of ;7–11% per year (12).”
BackgroundMethodResultInfluentialHyperinsulinemia in African-American Children
Arslanian, S. A., Saad, R., Lewy, V., Danadian, K., & Janosky, J. (2002) · Diabetes · doi:10.2337/diabetes.51.10.3014 · Cited by 236 · cited 1×
“In addition, differences in insulin clearance in different racial groups (21,22) could confound the insulinogenic index data.”
BackgroundThe Rosiglitazone Story — Lessons from an FDA Advisory Committee Meeting
Rosen, C. J. (2007) · New England Journal of Medicine · doi:10.1056/nejmp078167 · Cited by 207 · cited 1×
“However, TODAY was designed and initiated prior to the discovery of the adverse effects of rosiglitazone (26).”
BackgroundGungor, N., Bacha, F., Saad, R., Janosky, J., & Arslanian, S. (2005) · Diabetes Care · doi:10.2337/diacare.28.3.638 · Cited by 186
Cited by
Items 101–200 of 288
Youth-onset Type 2 Diabetes: An Overview of Pathophysiology, Prognosis, Prevention and Management
Titmuss, A., Korula, S., Wicklow, B. A., & Nadeau, K. J. (2024) · Current Diabetes Reports · doi:10.1007/s11892-024-01546-2 · Cited by 46
“At baseline, 8% of youth in TODAY had diabetic kidney disease (DKD), increasing to 54.8% by 15 years, 19.2% had hypertension (increasing to 67.5”
BackgroundInfluentialThe Rise of Type 2 Diabetes in Children and Adolescents: An Emerging Pandemic
Goyal, S., & Vanita, V. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70029 · Cited by 48
“The TODAY study found a 20%–35% yearly loss in β ‐cell function in adolescents aged 10–19 years with T2DM, compared to a 7% decline in older adults with T2DM [82].”
Lipid Profiles, Inflammatory Markers, and Insulin Therapy in Youth with Type 2 Diabetes
Katz, L. E. L., Bacha, F. F., Gidding, S. S., Weinstock, R. S., ghormli, L. K. E., Libman, I. M., Nadeau, K. J., Porter, K., Marcovina, S. M., McKay, S. V., et al. (2018) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2017.12.052 · Cited by 33
Pediatric Diabetes on the Rise: Trends in Incident Diabetes During the COVID-19 Pandemic
Modarelli, R. E., Sarah, S., Ramaker, M. E., Bolobiongo, M., Benjamin, R. W., & Balikcioglu, P. G. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac024 · Cited by 34
Hu, Y., XING, H., Dong, X., Lu, W., Xiao, X., Gao, L., Cui, M., & Chen, J. (2015) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2015.2593 · Cited by 30
“The TODAY Study Group found that pioglitazone combined with metformin is better than metformin alone when used on patients with type 2 diabetes mellitus (18).”
MethodChanging the Concept of Type 2 Diabetes: Beta Cell Workload Hypothesis Revisited
Saisho, Y. (2018) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530318666180821161825 · Cited by 30
Nadeau, K. J., Mayer‐Davis, E. J., Gubitosi‐Klug, R., Zeitler, P. S., Kahn, S. E., Dabelea, D., & SEARCH, T. (2025) · Diabetes Care · doi:10.2337/dc25-0001 · Cited by 39
Sato, S., Saisho, Y., Kou, K., Meguro, S., Tanaka, M., Irie, J., Kawai, T., & Itoh, H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121988 · Cited by 29
Wu, H., Yang, A., Lau, E. S. H., Zhang, X., Fan, B., Shi, M., Huang, C., Ronald, C. W., Kong, A. P. S., Chow, E., et al. (2023) · PLoS Medicine · doi:10.1371/journal.pmed.1004261 · Cited by 31
“In addition to clinical inertia and insufficient management guidelines for young-onset type 2 diabetes [23], people with type 2 diabetes diagnosed at a younger age have more rapid deterioration of β-cell function [24], worse metabolic risk profiles [25], and poorer response to glucose-lowering treatment [26] than thos…”
BackgroundStagi, S., Ricci, F., Bianconi, M., Sammarco, M., Municchi, G., Toni, S., Lenzi, L., Verrotti, A., & de Martino, M. (2017) · Nutrients · doi:10.3390/nu9050524 · Cited by 32
“While results from long term follow-up are very rare [52,53], they seem to show a reduction in the effects of metformin on metabolic and adiposity parameters [53], strengthening our results.”
ResultClinical Trials in Youth-Onset Type 2 Diabetes: Needs, Barriers, and Options
Zeitler, P., Chou, H. S., Copeland, K. C., & Geffner, M. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0597-2 · Cited by 26
“TODAY” Reflects on the Changing “Faces” of Type 2 Diabetes
Cefalu, W. T. (2013) · Diabetes Care · doi:10.2337/dc13-0765 · Cited by 26
Zeitler, P. S. (2019) · World Journal of Pediatrics · doi:10.1007/s12519-019-00247-1 · Cited by 28
Bacha, F. F., Cheng, P., Gal, R. L., Beaulieu, L. C., Kollman, C., Adolph, A. L., Shoemaker, A. H., Wolf, R. M., KLINGENSMITH, G. J., & Tamborlane, W. V. (2021) · Diabetes Care · doi:10.2337/dc21-0143 · Cited by 29
Bianco, M. E., Kuang, A., Josefson, J. L., Catalano, P. M., Dyer, A. R., Lowe, L. P., Metzger, B. E., Scholtens, D. M., & Lowe, W. L. (2020) · Diabetologia · doi:10.1007/s00125-020-05331-0 · Cited by 29
Youth prediabetes and type 2 diabetes: Risk factors and prevalence of dysglycaemia
Saleh, M. W., Kim, J. Y., March, C. A., Gebara, N. Y., & Arslanian, S. A. (2021) · Pediatric Obesity · doi:10.1111/ijpo.12841 · Cited by 27
“Moreover, the deterioration in β-cell function in youth-T2D is accelerated, at ~20%–35% per year decline, compared with observations in adults, of ~7%–10% decline per year.(8,13,14) Against this background of high therapeutic failure rates in response to metformin, and the rapidly deteriorating β-cell function, treatm…”
BackgroundManagement of type 2 diabetes in young adults aged 18–30 years: ADS/ADEA/APEG consensus statement
Wong, J., Ross, G. P., Zoungas, S., Craig, M. E., Davis, E. A., Donaghue, K. C., Maple‐Brown, L. J., McGill, M. J., Shaw, J. E., Speight, J., et al. (2022) · Medical Journal of Australia · doi:10.5694/mja2.51482 · Cited by 26
Fan, Y., Fan, B., Lau, E. S. H., Lim, C. K. P., Wu, H., Ronald, C. W., Ozaki, R., Kong, A. P. S., Chow, E., Luk, A. O. Y., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110954 · Cited by 28
Impact of lifestyle behavior change on glycemic control in youth with type 2 diabetes
Kriska, A. M., ghormli, L. K. E., Copeland, K. C., HIGGINS, J. A., Ievers‐Landis, C. E., Katz, L. E. L., Trief, P. M., Wauters, A. D., Yasuda, P. M., Delahanty, L. M., et al. (2017) · Pediatric Diabetes · doi:10.1111/pedi.12526 · Cited by 33
Bacha, F. F., Cheng, P., Gal, R. L., Kollman, C., Tamborlane, W. V., KLINGENSMITH, G. J., Manseau, K., Wood, J., & Beck, R. W. (2017) · Hormone Research in Paediatrics · doi:10.1159/000481687 · Cited by 25
Youth with type 2 diabetes have hepatic, peripheral, and adipose insulin resistance
Cree‐Green, M., Wiromrat, P., Stuppy, J. J., Thurston, J. E., Bergman, B. C., Baumgartner, A., Bacon, S. D., Scherzinger, A. L., Pyle, L. L., & Nadeau, K. J. (2018) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00258.2018 · Cited by 26
Tryggestad, J. B., Shah, R. D., Braffett, B. H., Bacha, F. F., Gidding, S. S., Gubitosi‐Klug, R., SHAH, A. S., Urbina, E. M., Katz, L. E. L., & for the TODAY Study Group (2020) · Pediatric Diabetes · doi:10.1111/pedi.13062 · Cited by 26
Huynh, E., Rand, D., McNeill, C., Brown, S., Sénéchal, M., Wicklow, B. A., Dart, A. B., Sellers, E. A. C., Dean, H., Blydt‐Hansen, T. D., et al. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.09.093 · Cited by 29
Pediatric Type 2 Diabetes: Not a Mini Version of Adult Type 2 Diabetes
Hitt, T. A., & Katz, L. E. L. (2020) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2020.08.003 · Cited by 24
Nephropathy in Youth and Young Adults with Type 2 Diabetes
Solis‐Herrera, C., Triplitt, C. L., & Lynch, J. L. (2014) · Current Diabetes Reports · doi:10.1007/s11892-013-0456-y · Cited by 27
Alemi, H., Khaloo, P., Rabizadeh, S., Mansournia, M. A., Mirmiranpour, H., Salehi, S. S., Esteghamati, A., & Nakhjavani, M. (2018) · Cell Stress and Chaperones · doi:10.1007/s12192-018-0942-x · Cited by 25
Developing services to support the delivery of care to people with early‐onset type 2 diabetes
Misra, S., Gable, D., Khunti, K., Barron, E., Young, B., Kar, P., & Valabhji, J. (2022) · Diabetic Medicine · doi:10.1111/dme.14927 · Cited by 23
Changes in Visceral and Subcutaneous Fat in Youth With Type 2 Diabetes in the TODAY Study
Dhaliwal, R., Shepherd, J., ghormli, L. K. E., Copeland, K. C., Geffner, M. E., HIGGINS, J. A., Levitsky, L. L., Nadeau, K. J., Weinstock, R. S., & White, N. H. (2019) · Diabetes Care · doi:10.2337/dc18-1935 · Cited by 21
Wu, Y., Wang, Y., Zhang, J., Zhang, R., Zhao, L., Ren, H., Zou, Y., Wang, T., Wang, J., Zhao, Y., et al. (2021) · Aging · doi:10.18632/aging.202624 · Cited by 25
“As TODAY Study indicated, patients with early-onset T2DM had accelerated decline of β-cell function than those with later-onset [26].”
Kahn, S. E., Mather, K. J., Arslanian, S. A., Barengolts, E., Buchanan, T. A., Caprio, S., Ehrmann, D. A., Hannon, T. S., Marcovina, S. M., Nadeau, K. J., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0460 · Cited by 22
Beamish, A. J., D’Alessio, D. A., & Inge, T. H. (2015) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2015.03.006 · Cited by 21
Kelsey, M. M., Hilkin, A. M., Pyle, L., Severn, C., Utzschneider, K. M., Pelt, R. E. V., Zeitler, P. S., & Nadeau, K. J. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab170 · Cited by 20
TODAY Study Group, TODAY Study Group, HIGGINS, J. A., Chernausek, S. D., ghormli, L. K. E., ISGANAITIS, E. M., Kelsey, M. M., Marcus, M. D., McKay, S. V., Siska, M., et al. (2022) · Diabetes Care · doi:10.2337/dc22-0784 · Cited by 22
Self-citationParental Income Level and Risk of Developing Type 2 Diabetes in Youth
Yen, F., Wei, J. C., Liu, J., Hwu, C., & Hsu, C. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.45812 · Cited by 24
Drugs for the treatment of pediatric type 2 diabetes mellitus and related co-morbidities
Tabatabaei‐Malazy, O., Nikfar, S., Larijani, B. A., & Abdollahi, M. R. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1258057 · Cited by 22
Youth-onset type 2 diabetes: translating epidemiology into clinical trials
Pyle, L. L., & Kelsey, M. M. (2021) · Diabetologia · doi:10.1007/s00125-021-05480-w · Cited by 22
Thrailkill, K. M., Bunn, R. C., Uppuganti, S., Ray, P. D., Popescu, I. R., Kalaitzoglou, E., Fowlkes, J. L., & Nyman, J. S. (2020) · Bone · doi:10.1016/j.bone.2020.115625 · Cited by 22
“Unlike adults with T2D, youth-onset T2D also displays a more aggressive phenotype (7, 8), characterized by: 1) a more rapid decline in ß-cell function (10, 11); 2) a more rapid deterioration in glycemic control (11), requiring multi-drug therapy; and 3) an earlier onset and more rapid progression of both microvascular…”
BackgroundObesity, Body Image Dissatisfaction, and Sexual Dysfunction: A Narrative Review
McNabney, S. M. (2022) · Sexes · doi:10.3390/sexes3010002 · Cited by 28
Borges, R. D. S., Conegundes, A. F., de Paula, L. H., dos Santos, R. L. C., Alves, S. N., Machado, R. A., Viana, I. B., & Silva, A. C. S. E. (2024) · Pediatric Diabetes · doi:10.1155/2024/6295345 · Cited by 23
Gregg, B. E., Connor, C. G., Cheng, P., Ruedy, K. J., Beck, R. W., Kollman, C., Schatz, D., Cengiz, E., Tamborlane, W. V., KLINGENSMITH, G. J., et al. (2015) · Pediatric Diabetes · doi:10.1111/pedi.12280 · Cited by 18
Baek, H.-S., Park, J., Yu, J. S., Lee, J., Yang, Y., Ha, J., Lee, S., Cho, J., Lim, D., & Kim, H. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.1501 · Cited by 24
Bacha, F. F., ghormli, L. K. E., Arslanian, S. A., Zeitler, P. S., Laffel, L. M., Katz, L. E. L., Gandica, R., CHANG, N. T., Sprague, J., MacLeish, S. A., et al. (2019) · Pediatric Diabetes · doi:10.1111/pedi.12906 · Cited by 18
Self-citationType 2 diabetes in children and adolescents: Challenges for treatment and potential solutions
Jia, I. L. J., Zampetti, S., Pozzilli, P., & Buzzetti, R. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111879 · Cited by 31
Zeitler, P. S., ghormli, L. K. E., Arslanian, S. A., Caprio, S., ISGANAITIS, E. M., Kelsey, M. M., Weinstock, R. S., White, N. H., & Drews, K. L. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac254 · Cited by 17
Wang, Y., Xu, W., Mak, I. L., Chin, W. Y., Yu, E. Y. T., Lam, C. L. K., & Wan, E. Y. F. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.101999 · Cited by 18
Suzuki, K., Niida, T., Yuki, H., Kinoshita, D., Fujimoto, D., Lee, H., McNulty, I. A., Takano, M., Nakamura, S., Kakuta, T., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.031474 · Cited by 18
Wang, J., Kang, J., Wu, C., Peng, T., Liao, L., Lee, M., Lee, J., & Chen, S. (2024) · Obesity Reviews · doi:10.1111/obr.13686 · Cited by 15
Wang, Y., Liu, S., Ying, L., Zhang, K., Li, H., Liang, N., Xiao, L., & Luo, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910534 · Cited by 20
“Regardless of the specific therapeutic interventions employed, impaired β -cell function at this stage is linked to poor glycemic control [5–7].”
BackgroundGlycemic control in youth‐onset type 2 diabetes correlates with weight loss
CHANG, N. T., Yeh, M. Y., Raymond, J. K., Geffner, M. E., Ryoo, J. H., & Chao, L. C. (2020) · Pediatric Diabetes · doi:10.1111/pedi.13093 · Cited by 16
Type 2 diabetes in children and adolescents: distinct characteristics and evidence-based management
Karavanaki, K., Paschou, S. Α., Tentolouris, N., Karachaliou, F., & Soldatou, A. (2022) · Endocrine · doi:10.1007/s12020-022-03172-y · Cited by 22
Significant retinopathy in young-onset type 2 vs. type 1 diabetes: a clinical observation
Song, S. H. (2016) · International Journal of Clinical Practice · doi:10.1111/ijcp.12789 · Cited by 17
Elder, D. A., Hornung, L. N., Khoury, J. C., & D’Alessio, D. A. (2017) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2017.06.007 · Cited by 15
Tamborlane, W. V., Chang, P.-Y., Kollman, C., KLINGENSMITH, G. J., Ruedy, K. J., Gal, R. L., Name, M. A. V., Bacha, F. F., Willi, S. M., & Beck, R. W. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12763 · Cited by 16
Weinstock, R. S., Trief, P. M., ghormli, L. K. E., Goland, R., McKay, S. V., Milaszewski, K., Preske, J., Willi, S. M., & Yasuda, P. M. (2015) · Diabetes Care · doi:10.2337/dc14-2393 · Cited by 21
Tung, J. Y., Kwan, E., But, B. W. M., Wong, W. H. S., Fu, A. C., Pang, G. S.-W., Tsang, J. W., Yau, H., Belaramani, K. M., Wong, L., et al. (2021) · Pediatric Diabetes · doi:10.1111/pedi.13231 · Cited by 14
Pramanik, S., Mondal, S., Palui, R., & Ray, S. (2024) · World Journal of Clinical Pediatrics · doi:10.5409/wjcp.v13.i2.91587 · Cited by 24
Approach to the Patient: Youth-Onset Type 2 Diabetes
Hitt, T. A., Hannon, T. S., & Magge, S. N. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad482 · Cited by 15
Current Perspectives for Treating Adolescents with Obesity and Type 2 Diabetes: A Review
Niechciał, E., Wais, P., Bajtek, J., & Kędzia, A. W. (2024) · Nutrients · doi:10.3390/nu16234084 · Cited by 26
Metformin in the Treatment of Obese Children and Adolescents at Risk of Type 2 Diabetes
Kendall, D., Amin, R., & Clayton, P. (2013) · Pediatric Drugs · doi:10.1007/s40272-013-0045-1 · Cited by 13
Intensive Therapy in Newly Diagnosed Type 2 Diabetes: Results of a 6-Year Randomized Trial
Harrison, L., ADAMS-HUET, B. A., Li, X., Raskin, P., & Lingvay, I. (2014) · Journal of Investigative Medicine · doi:10.2310/jim.0000000000000068 · Cited by 14
Srugo, S. A., MORRISON, H. I., Villeneuve, P. J., de Groh, M., & Jiang, Y. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.11.002 · Cited by 13
Real-Life Glycemic Control in Children with Type 2 Diabetes: A Population-Based Study
Meyerovitch, J., Zlotnik, M., Yackobovitch‐Gavan, M., Phillip, M., & Shalitin, S. (2017) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2017.05.074 · Cited by 13
Diabetes tipo 2 infantojuvenil
Bernal, M., & Aguilar, J. M. V. (2018) · Revista Clínica Española · doi:10.1016/j.rce.2018.03.020 · Cited by 18
Meyers, A. G., Hudson, J., Cravalho, C. K. L., Matta, S. T., VILLALOBOS-PEREZ, A., Cogen, F. R., & Chung, S. T. (2020) · Pediatric Diabetes · doi:10.1111/pedi.13148 · Cited by 14
“At diagnosis, up to half of youth require intensive insulin therapy,(3) and a similar percentage who are treated with metformin monotherapy require additional anti-hyperglycemic agents within 2 years of diagnosis.(4) The reduced long-term efficacy of metformin in youth starkly contrasts data in adults.”
BackgroundThe TODAY Study Group (2020) · Diabetes Care · doi:10.2337/dc20-0622 · Cited by 13
“in participants with glycemic failure, irrespective of treatment arm (5).”
BackgroundResultInfluentialSelf-citationManejo de la diabetes mellitus tipo 2 en adolescentes y adultos jóvenes en atención primaria
Miravet-Jiménez, S., Pérez-Unanua, M. P., Alonso-Fernández, M., Lavado, F. J. E., Loro, B. G.-M., & Carbonell, A. M. P. (2020) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2019.11.008 · Cited by 25
Sessa, A. D., Grandone, A., Marzuillo, P., Umano, G. R., Cirillo, G., & del Giudice, E. M. (2021) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2020-0684 · Cited by 17
Unmet Needs in the Treatment of Childhood Type 2 Diabetes: A Narrative Review
Tamborlane, W. V., & Shehadeh, N. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02642-7 · Cited by 12
“Evidence shows that T2D progresses more rapidly in younger patients, with yearly beta-cell function deterioration found to be 20–35% in youth with T2D[13] versus 7–11% in adults with T2D [14], despite similar disease durations.”
BackgroundFerreira, M. K. A., Freitas, W. P. O., Barbosa, I. M., da Rocha, M. N., da Silva, A. W., Rebouças, E. D. L., Mendes, F. R. D. S., Alves, C. R., Nunes, P. I. G., Marinho, M. M., et al. (2023) · 3 Biotech · doi:10.1007/s13205-023-03696-8 · Cited by 14
Beta‐cell function in type 2 diabetes ( T2DM ): Can it be preserved or enhanced?
Kassem, L. S., Rajpal, A., Barreiro, M. V. E., & Ismail‐Beigi, F. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13446 · Cited by 16
“161”
Patel, T., Ayub, A., Bone, J. N., Hadjiyannakis, S., Henderson, M., Nour, M. A., Pinto, T. E., Wicklow, B. A., Hamilton, J. K., Sellers, E. A. C., et al. (2023) · Pediatric Diabetes · doi:10.1155/2023/5511049 · Cited by 16
“The TODAY trial showed that metformin alone or combined with insulin does not curb the rapid decline in β -cell function (reported to be twice that of adults) in the subpopulations of children [29, 30].”
BackgroundMetformin therapy in pediatric type 2 diabetes mellitus and its comorbidities: A review
Alfaraidi, H., & Samaan, M. C. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1072879 · Cited by 13
Pharmacological interventions for preventing or delaying onset of type 2 diabetes mellitus
Bethel, M. A., Xu, W., & Theodorakis, M. J. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12401 · Cited by 13
“Similarly, metformin has conclusively been shown not to prevent the gradual decline in β-cell function, a hallmark of type 2 diabetes progression [11,12].”
BackgroundCan We RISE to the Challenge of Youth-Onset Type 2 Diabetes?
Buse, J. B., D’Alessio, D. A., & Riddle, M. C. (2018) · Diabetes Care · doi:10.2337/dci18-0025 · Cited by 11
Young‐onset type 2 diabetes: A neglected group requiring urgent attention
Song, S. H., & Frier, B. M. (2022) · Diabetic Medicine · doi:10.1111/dme.14903 · Cited by 11
Wolfgram, P. M., Connor, E. L., Rehm, J. L., Eickhoff, J. C., Zha, W., Reeder, S. B., & Allen, D. B. (2015) · Hormone Research in Paediatrics · doi:10.1159/000439130 · Cited by 12
Management of Early-Onset Type 2 Diabetes in Adults: Current Evidence and Future Directions
Savage, M. J., Goldney, J., Slater, T., Sarkar, P., Sargeant, J. A., Wilmot, E. G., & Davies, M. J. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0561 · Cited by 11
“…with T2DM experienced a 20% to 35% annual decline in β-cell function, which is significantly higher than the ~7% decline seen in older individuals [43-45]. β-Cell dysfunction is associated with impaired glycemic control and a greater likelihood of treatment failure in both younger and older…”
Young‐onset type 2 diabetes—Epidemiology, pathophysiology, and management
Luk, A. O. Y., Wu, H., Fan, Y., Fan, B., O, C. K., & Chan, J. C. N. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.70081 · Cited by 13
“Studies have found that youth-onset type 2 diabetes is associated with an annual decline in beta-cell function of 20 – 35% 94 – 97 , while individuals diagnosed in adulthood experience a loss of beta-cell function at an annual rate of 7 – 11% 98,99 .”
Vajravelu, M. E., Hitt, T. A., Amaral, S. G., Katz, L. E. L., Lee, J. M., & Kelly, A. T. (2021) · Pediatric Diabetes · doi:10.1111/pedi.13232 · Cited by 10
Utzschneider, K. M., Younes, N., Butera, N. M., Balasubramanyam, A., Bergenstal, R. M., Barzilay, J. I., Desouza, C. V., DeFronzo, R. A., Elasy, T. A., Krakoff, J. A., et al. (2024) · Diabetes Care · doi:10.2337/dc23-1059 · Cited by 12
Dietary Behaviors and Glucose Metabolism in Young Adults at Risk for Type 2 Diabetes
Cha, E., Paul, S., Braxter, B., Umpierrez, G. E., & Faulkner, M. S. (2018) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721718756057 · Cited by 12
Xu, Z., Du, H., Cui, L., Zheng, R., Li, G., Wei, H., Lu, F., Chen, L.-L., Wu, C., Zhang, S.-X., et al. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i8.1292 · Cited by 11
Redling, D. M., Bialak, S., ghormli, L. K. E., Chernausek, S. D., Jones, K., & Tryggestad, J. B. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae376 · Cited by 8
Zhang, F.-S., Li, H., Yu, X. M., Song, Y., Ren, Y., Qian, X.-Z., Liu, J.-L., Li, W.-X., Huang, Y., & Gao, K. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i1.96032 · Cited by 11
Clinical course of adolescents with type 2 diabetes mellitus: A nationwide cohort study in Taiwan
Yen, F., Wei, J. C., Liu, J., Hsu, C., & Hwu, C. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13873 · Cited by 9
TODAY Study Group, Nadeau, K. J., ghormli, L. K. E., Arslanian, S. A., Bacha, F. F., Caprio, S., Chan, C. L., Chao, L. C., Rayas, M. S., Siska, M., et al. (2023) · Diabetes Care · doi:10.2337/dc23-0560 · Cited by 10
Self-citationCardiovascular complications of type 2 diabetes in youth
Kehler, D. S., Stammers, A. N., Susser, S. E., Hamm, N. C., Kimber, D. E., Hlynsky, M. W., & Duhamel, T. A. (2014) · Biochemistry and Cell Biology · doi:10.1139/bcb-2014-0118 · Cited by 11
Kaar, J. L., Schmiege, S. J., Drews, K. L., HIGGINS, J. A., Walders‐Abramson, N., ISGANAITIS, E. M., Willi, S. M., Marcus, M. D., Zeitler, P. S., & Kelsey, M. M. (2019) · Pediatric Diabetes · doi:10.1111/pedi.12976 · Cited by 9
“The details of the TODAY study have been previously published.(14,15) The main objective of the original study was to examine the relative efficacy of three treatments: (a) Metformin (Met), (b) Met + Rosiglitazone (Rosi), and (c) Met + Lifestyle.”
MethodLu, C., Wolfs, D., ghormli, L. K. E., Levitsky, L. L., Katz, L. E. L., Laffel, L. M., Patti, M., & ISGANAITIS, E. M. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.0447 · Cited by 12
Seo, J. Y., Lee, C. G., Choi, H. S., Lee, H. K., Lee, S. Y., Kim, H., Jung, K. Y., & Kim, J. T. (2023) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2244196.098 · Cited by 8
Concepción, J., Chen, K., Saito, R., Gangoiti, J. A., Mendez, E., Nikita, M. E., Barshop, B. A., Natarajan, L., Sharma, K. K., & Jj, K. (2021) · Yearbook of pediatric endocrinology · doi:10.1530/ey.18.12.2 · Cited by 7
Circulating Metabolite Biomarkers of Glycemic Control in Youth-Onset Type 2 Diabetes
Chen, Z., Lu, C., Dreyfuss, J. M., Tiwari, G., Shi, X. D., Zheng, S., Wolfs, D., Pyle, L. L., Bjornstad, P., ghormli, L. K. E., et al. (2024) · Diabetes Care · doi:10.2337/dc23-2441 · Cited by 9
Insulin Dynamics and Pathophysiology in Youth-Onset Type 2 Diabetes
Abu-Nejem, R., & Hannon, T. S. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae463 · Cited by 8
Sauder, K. A., Stafford, J. M., Ehrlich, S. R., Lawrence, J. M., Liese, A. D., Marcovina, S. M., Mottl, A. K., Pihoker, C., Saydah, S., SHAH, A. S., et al. (2021) · Diabetes Care · doi:10.2337/dc20-2983 · Cited by 7
Intervention with Therapeutic Agents, Understanding the Path to Remission in Type 2 Diabetes
Hao, S., Umpierrez, G. E., Daley, T. C., & Vellanki, P. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.07.003 · Cited by 7
Hannon, T. S., Edelstein, S. L., Arslanian, S. A., Caprio, S., Zeitler, P. S., Buchanan, T. A., Ehrmann, D. A., Mather, K. J., Tripputi, M., Kahn, S. E., et al. (2020) · Pediatric Diabetes · doi:10.1111/pedi.13129 · Cited by 7
“line differences or change over time in insulin sensitivity (1/fasting insulin).(22) Our results reflect similar OGTT β-cell response outcomes despite the fact that the RISE participants had either IGT or more”
ResultReassessing type 2 diabetes in adolescents and its management strategies based on insulin resistance
Jia, Q.-Y., Zhang, Y., Zhang, B., & An, X. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1377918 · Cited by 11
Further RISE’ing to the Challenge of Type 2 Diabetes in Youth
Klein, K. R., & Buse, J. B. (2021) · Diabetes Care · doi:10.2337/dci21-0023 · Cited by 8
Considering metformin as a second-line treatment for children and adolescents with prediabetes
Hosey, C. M., Halpin, K. L., & Yan, Y. (2022) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2021-0200 · Cited by 6
Carydias, E., Tasho, A., Kani, C., Bacopoulou, F., Stefanaki, C., & Markantonis, S. L. (2022) · Children · doi:10.3390/children9101572 · Cited by 5
Metadata
- Authors
- TODAY Study Group
- Corresponding author
- TODAY Study Group
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-05-15
- Volume
- 36
- Issue
- 6
- Pages
- 1749-1757
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3661836
- OpenAlex
- W59232989
- Cited by
- 288
- References
- 25
- Citations by year
- 2026: 10 · 2025: 26 · 2024: 30 · 2023: 25 · 2022: 37 · 2021: 28 · 2020: 27 · 2019: 16 · 2018: 23 · 2017: 12 · 2016: 12 · 2015: 16 · 2014: 18 · 2013: 8
- FWCI
- 14.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (UL1TR000130, UL1TR000005, UL1TR000448, UL1TR000439)
- National Institute of Diabetes and Digestive and Kidney Diseases (U01DK061239, U01DK061212, U01DK061254, U01DK061242, U01DK061230)
- National Center for Research Resources (M01RR000125, UL1RR024989, UL1RR025758, M01RR001066, UL1RR024153, UL1RR024134, M01RR000043, M01‐RR00043‐45, M01RR014467, M01RR000069, UL1RR024992, UL1RR024139, M01RR000084, M01RR000036, UL1RR025780)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- metformin, rosiglitazone, insulin sensitivity, beta-cell function, oral disposition index, insulinogenic index, treatment failure, beta-cell reserve
- MeSH terms
- Adolescent, Child, Diabetes Mellitus, Type 2, Drug Combinations, Female, Humans, Hypoglycemic Agents, Insulin Resistance, Life Style, Male, Metformin, Thiazoles, Insulin-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.